Unlike the unified US system, running a multi-country clinical trial in Europe is a bureaucratic nightmare. A single trial can require three slightly different protocols for Switzerland, the UK, and Spain, for example, creating significant delays, costs, and complexity for investigators.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Walgreens prioritizes tackling barriers to medication access—such as cost and prior authorizations—believing that adherence can only be addressed once a patient can consistently obtain their therapy. This frames the two issues as a sequence, not parallel challenges.

Eli Lilly ran the fastest-accrued Alzheimer's study in history by going direct-to-patient. This model, using televisits and centralized diagnostics, is highly effective for preventative medicines where motivated patients can be recruited online.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Industry leaders often believe their clinical trial designs are patient-centric, but direct experience in community clinics reveals the significant burden placed on patients and caregivers, such as 12-hour blood draw days. This exposure leads to more practical and humane trial designs that improve real-world data collection.